HMI-203(Homology Medicines)

N/A

Report date: 2023/10/26 16:53:39

Base Information

Drug NameHMI-203(Homology Medicines)
Drug Alias NameHMI-203
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionIduronate-2-sulfatase gene transference
TargetsGlycosaminoglycanIduronate-2-sulfatase
Therapy Area/IndicationsMucopolysaccharidosis II
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesQ32 Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesQ32 Bio Inc
Inactive CompaniesN/A
Active IndicationsMucopolysaccharidosis II
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A